From PCOS to PMOS: why medicine is renaming a commonly misunderstood condition

For decades, a diagnosis of polycystic ovary syndrome has come bundled with a word that doesn't quite fit. Most women who receive it have follicles, not cysts. The "polycystic" appearance of their ovaries on ultrasound, that ring of small follicles, is not a disease in itself. It's a finding. And yet the name has stuck, quietly shaping how millions of women, their doctors, and the research community understand the condition for over 80 years.

That has now changed. As of 12 May 2026, PCOS has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS), following a major international consensus published in The Lancet. It sounds like a minor administrative update. It isn't.

What the old name "PCOS" got wrong

The label polycystic ovary syndrome was coined in 1935, when the condition was first described as Stein-Leventhal syndrome. At the time, enlarged ovaries with multiple follicles were the defining observable feature. The name followed the anatomy.

The problem is that medicine has moved on. We now understand PCOS primarily as a hormonal and metabolic condition, one defined by excess androgen production, irregular or absent ovulation, and disrupted menstrual cycles. The ovarian morphology is one possible feature among several, not the disease itself. And critically, around 20 to 30 percent of women with otherwise normal hormone levels and regular cycles show the same "polycystic" appearance on ultrasound. Meanwhile, some women who fully meet the diagnostic criteria for PCOS show no polycystic appearance at all.

What PMOS is, and what the change implies 

The new name, polyendocrine metabolic ovarian syndrome shifts the emphasis from an isolated ovarian disorder to a multisystemic syndrome with neuroendocrine, metabolic, and reproductive features. 

But the renaming goes further than wording. The diagnostic criteria established in Rotterdam in 2003, which requires at least two of the following: irregular or absent menstrual cycles, clinical or biochemical androgenism and ovarian cysts visible on ultrasound is still valid. The new name aims to improve timely diagnosis, expand treatment options, reduce stigma, increase research and funding, and help women better understand their symptoms. 

Why diagnosis has often been harder than it should be

PCOS is one of the most common hormonal conditions affecting women of reproductive age, with estimates of one in ten women globally. In Switzerland, as across Europe, it remains substantially underdiagnosed. Studies suggest that up to 70 percent of affected women may not have a formal diagnosis at the time they seek care for related symptoms.

Part of the reason is the symptom range. PCOS manifests differently in different women. Some experience irregular or absent periods. Others have acne, excess facial or body hair, or hair loss. Many have difficulty managing weight or show signs of insulin resistance. Some have all of these; others have only one or two. 

The name hasn't helped. "Ovary syndrome" anchors the condition in gynecology, when much of its burden, the insulin resistance, the cardiovascular risk, the metabolic dysregulation, lives elsewhere in the body. Research has shown that women with PCOS have elevated long-term risks for type 2 diabetes, cardiovascular disease, endometrial cancer, and mental health conditions including anxiety and depression. A name that points to the ovaries alone understates the systemic nature of what's happening and delays comprehensive treatment

The stigma that a name carries

Names do more than describe: they shape how patients are treated and how they understand themselves. Research into the patient experience of PCOS has consistently found that the word "cysts" is one of the first things women fixate on after diagnosis. It implies something wrong with the ovaries specifically, something that might affect fertility, something that sounds more serious than "a hormonal pattern that can be managed."

The result is unnecessary anxiety about ovarian health, sometimes at the expense of addressing the features that most affect long-term wellbeing: metabolic function, cycle regularity, and hormonal balance.

There is also a subtler effect. When a condition sounds primarily structural and gynecological, it tends to be referred to gynecologists and treated symptom by symptom. Acne treated by a dermatologist. Irregular periods managed with hormonal contraception. Weight concerns sent to a nutritionist. The systemic picture, the one that requires coordinated care across endocrinology, nutrition, and sometimes cardiology, can get lost in the referral chain.

A name that reflects what the disease actually is, a reproductive and metabolic condition driven largely by androgen excess and insulin signaling disruption, might shift that pattern. 

What this means for women in Switzerland

For women in Switzerland navigating a PMOS diagnosis, or suspecting they have one, the practical reality is that a thorough workup goes beyond what a standard check-up typically covers. A GP consultation can establish a suspected diagnosis and initiate a referral, but a thorough workup requires blood tests that go beyond the basic hormone panels typically ordered in a standard check-up.

The most useful markers include total and free testosterone, SHBG (sex hormone-binding globulin), LH and FSH, AMH (anti-Müllerian hormone), fasting glucose, fasting insulin, and a full lipid panel. Together, these give a picture of both the hormonal pattern and the metabolic risk, which are the two axes that most determine long-term outcomes. An ultrasound to assess ovarian morphology is one piece of the puzzle, not the whole picture.

Understanding which markers matter, and what your results actually mean, is where the gap often sits. A comprehensive blood panel, one that goes well beyond what a standard annual check-up includes, is the starting point for anyone who wants to understand what's driving their symptoms rather than managing them one at a time.

How Ahead approaches hormonal and metabolic health

For women who want a clearer picture of their hormonal and metabolic status, Ahead's [advanced blood panel](https://www.aheadhealth.com/biomarkers) with an hormone add-on includes the markers most relevant to PCOS assessment: testosterone (total and free), SHBG, LH, FSH, fasting glucose, fasting insulin, and a full lipid panel, alongside 80-plus additional biomarkers covering thyroid function, inflammation, and nutrient status.

This is also included in the Ahead Pro package (CHF 3,549), which combines the blood panel with a full-body MRI and a personalized health report reviewed by a Swiss board-certified physician. Results are reviewed in the context of your full picture, not as isolated numbers, the kind of joined-up assessment that a fragmented referral pathway rarely produces.

Ahead's services are designed to complement your GP and any specialist care you're already receiving, not replace them. Supplementary health insurers may cover part of the cost.

The broader argument: naming shapes understanding

The PCOS to PMOS debate is, at its core, about what medicine owes patients in terms of accuracy. A diagnosis is not just a label. It's the frame through which a person understands their own body for years, sometimes decades. When that frame is built around a misleading word, the downstream effects are real: unnecessary worry, misdirected treatment, fragmented care.

The researchers behind the *Lancet* consensus have made a case that better language is part of better medicine. That the name a condition carries shapes how it's taught in medical schools, how patients describe their symptoms, how insurers code it, and how scientists frame their research questions.

It's a slower kind of change than a new drug or a better scan. But for the estimated one in ten women living with this condition, it may be one of the more meaningful shifts in how they're seen and heard.

Conclusion

The move from PCOS to PMOS is not simply about updating an acronym. It's an argument that the words medicine uses matter, that a more accurate name can shift how a condition is explained, how patients understand it, and ultimately how it's managed. Whether the renaming gains full international adoption will depend on clinical bodies, medical schools, and the slow machinery of diagnostic consensus. But the direction is now on the record. The cysts were never really the point.